# Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease

> **NCT02150551** · PHASE1 · COMPLETED · sponsor: **Catherine Bollard** · enrollment: 1 (actual)

## Conditions studied

- Inflammatory Bowel Diseases

## Interventions

- **BIOLOGICAL:** Allogeneic bone marrow-derived mesenchymal stromal cells

## Key facts

- **NCT ID:** NCT02150551
- **Lead sponsor:** Catherine Bollard
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-07
- **Primary completion:** 2018-09-05
- **Final completion:** 2018-09-05
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2024-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02150551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02150551, "Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02150551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*